Literature DB >> 22499346

Phenotype difference between ALS patients with expanded repeats in C9ORF72 and patients with mutations in other ALS-related genes.

Stéphanie Millecamps1, Séverine Boillée, Isabelle Le Ber, Danielle Seilhean, Elisa Teyssou, Marine Giraudeau, Carine Moigneu, Nadia Vandenberghe, Véronique Danel-Brunaud, Philippe Corcia, Pierre-François Pradat, Nadine Le Forestier, Lucette Lacomblez, Gaelle Bruneteau, William Camu, Alexis Brice, Cécile Cazeneuve, Eric Leguern, Vincent Meininger, François Salachas.   

Abstract

BACKGROUND: Expanded GGGGCC hexanucleotide repeats in the promoter of the C9ORF72 gene have recently been identified in frontotemporal dementia (FTD), Amyotrophic Lateral Sclerosis (ALS) and ALS-FTD and appear as the most common genetic cause of familial (FALS) and sporadic (SALS) forms of ALS.
METHODS: We searched for the C9ORF72 repeat expansion in 950 French ALS patients (225 FALS and 725 SALS) and 580 control subjects and performed genotype-phenotype correlations.
RESULTS: The repeat expansion was present in 46% of FALS, 8% of SALS and 0% of controls. Phenotype comparisons were made between FALS patients with expanded C9ORF72 repeats and patients carrying another ALS-related gene (SOD1, TARDBP, FUS) or a yet unidentified genetic defect. SALS patients with and without C9ORF72 repeat expansions were also compared. The C9ORF72 group presented more frequent bulbar onset both in FALS (p<0.0001 vs SOD1, p=0.002 vs TARDBP, p=0.011 vs FUS, p=0.0153 vs other FALS) and SALS (p=0.047). FALS patients with C9ORF72 expansions had more frequent association with FTD than the other FALS patients (p<0.0001 vs SOD1, p=0.04 vs TARDBP, p=0.004 vs FUS, p=0.03 vs other FALS). C9ORF72-linked FALS patients presented an older age of onset than SOD1 (p=0.0139) or FUS mutation (p<0.0001) carriers. Disease duration was shorter for C9ORF72 expansion carriers than for SOD1 (p<0.0001) and TARDBP (p=0.0242) carriers, other FALS (p<0.0001) and C9ORF72-negative SALS (p=0.0006).
CONCLUSIONS: Our results confirm the major role of expanded repeats in C9ORF72 as causative for ALS and provide evidence for specific phenotypic aspects compared to patients with other ALS-related genes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22499346     DOI: 10.1136/jmedgenet-2011-100699

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  58 in total

Review 1.  C9ORF72 hexanucleotide repeats in behavioral and motor neuron disease: clinical heterogeneity and pathological diversity.

Authors:  Jennifer S Yokoyama; Daniel W Sirkis; Bruce L Miller
Journal:  Am J Neurodegener Dis       Date:  2014-03-28

Review 2.  The phenotypic variability of amyotrophic lateral sclerosis.

Authors:  Bart Swinnen; Wim Robberecht
Journal:  Nat Rev Neurol       Date:  2014-10-14       Impact factor: 42.937

Review 3.  The Genetics of C9orf72 Expansions.

Authors:  Ilse Gijselinck; Marc Cruts; Christine Van Broeckhoven
Journal:  Cold Spring Harb Perspect Med       Date:  2018-04-02       Impact factor: 6.915

Review 4.  How do C9ORF72 repeat expansions cause amyotrophic lateral sclerosis and frontotemporal dementia: can we learn from other noncoding repeat expansion disorders?

Authors:  Marka van Blitterswijk; Mariely DeJesus-Hernandez; Rosa Rademakers
Journal:  Curr Opin Neurol       Date:  2012-12       Impact factor: 5.710

5.  C9orf72 repeat expansions are a rare genetic cause of parkinsonism.

Authors:  Suzanne Lesage; Isabelle Le Ber; Christel Condroyer; Emmanuel Broussolle; Audrey Gabelle; Stéphane Thobois; Florence Pasquier; Karl Mondon; Patrick A Dion; Daniel Rochefort; Guy A Rouleau; Alexandra Dürr; Alexis Brice
Journal:  Brain       Date:  2013-02       Impact factor: 13.501

Review 6.  From animal models to human disease: a genetic approach for personalized medicine in ALS.

Authors:  Vincent Picher-Martel; Paul N Valdmanis; Peter V Gould; Jean-Pierre Julien; Nicolas Dupré
Journal:  Acta Neuropathol Commun       Date:  2016-07-11       Impact factor: 7.801

Review 7.  Positron emission tomography in amyotrophic lateral sclerosis: Towards targeting of molecular pathological hallmarks.

Authors:  Stefanie M A Willekens; Donatienne Van Weehaeghe; Philip Van Damme; Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-12-08       Impact factor: 9.236

8.  De novo nonsense mutation of the FUS gene in an apparently familial amyotrophic lateral sclerosis case.

Authors:  Andrea Calvo; Cristina Moglia; Antonio Canosa; Maura Brunetti; Marco Barberis; Bryan J Traynor; Giovanna Carrara; Consuelo Valentini; Gabriella Restagno; Adriano Chiò
Journal:  Neurobiol Aging       Date:  2013-12-27       Impact factor: 4.673

9.  Contribution of ATXN2 intermediary polyQ expansions in a spectrum of neurodegenerative disorders.

Authors:  Serena Lattante; Stéphanie Millecamps; Giovanni Stevanin; Sophie Rivaud-Péchoux; Carine Moigneu; Agnès Camuzat; Sandra Da Barroca; Emeline Mundwiller; Philippe Couarch; François Salachas; Didier Hannequin; Vincent Meininger; Florence Pasquier; Danielle Seilhean; Philippe Couratier; Véronique Danel-Brunaud; Anne-Marie Bonnet; Christine Tranchant; Eric LeGuern; Alexis Brice; Isabelle Le Ber; Edor Kabashi
Journal:  Neurology       Date:  2014-08-06       Impact factor: 9.910

10.  Absence of C9ORF72 expanded or intermediate repeats in autopsy-confirmed Parkinson's disease.

Authors:  Karen Nuytemans; Vanessa Inchausti; Gary W Beecham; Liyong Wang; Dennis W Dickson; John Q Trojanowski; Virginia M-Y Lee; Deborah C Mash; Matthew P Frosch; Tatiana M Foroud; Lawrence S Honig; Thomas J Montine; Ted M Dawson; Eden R Martin; William K Scott; Jeffery M Vance
Journal:  Mov Disord       Date:  2014-02-26       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.